Spark Therapeutics Inc (ONCE) Gross Profit Margin starting from the third quarter 2019 to third quarter 2018, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Spark Therapeutics Inc   (NASDAQ: ONCE)


Spark Therapeutics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONCE Gross Profit Margin (Sep 30 2019)
Q3 		(Jun 30 2019)
Q2 		(Mar 31 2019)
Q1 		(Dec 31 2018)
Q4 		(Sep 30 2018)
Q3
Y / Y Revenue Change 109.65 %
Seq. Revenue Change 66.24 %
Revenue In Millions $22.45
Gross Profit Margin 95.5 %
Gross Profit Margin Total Ranking # 271
Gross Profit In Millions $21.44
Y / Y Gross Profit Change 106.34 %
Seq. Gross Profit Change 75.63 %


Commenting Third Quarter 2019 Gross Profit Margin
Spark Therapeutics Inc Gross Profit grew by 75.63 % in Q3 sequentially to 21 millions, while Revenue increased by 66.24 %, this led to improvement in the company's Gross Profit Margin to 95.5 %, above the Spark Therapeutics Inc average Gross Profit Margin.


Observing third quarter 2019 results within Biotechnology & Pharmaceuticals industry 9 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 119 to 271.
Learn about Gross Margin
ONCE's Gross Profit Margin third quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 10
Healthcare Sector # 46
Overall # 258

Gross Profit Margin Statistics
High Average Low
98.93 % 93.72 % 84.07 %
(Jun 30 2018)   (Dec 31 2018)


ONCE Gross Income Trends • More of ONCE's Profitabilty Ratios • ONCE Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ONCE's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ONCE's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ONCE's Competitors
Gross Profit Margin Profit Margin for Spark Therapeutics Inc 's Suppliers
Gross Profit Margin Profit Margin for ONCE's Customers

You may also want to know
ONCE's Annual Growth Rates ONCE's Profitability Ratios ONCE's Asset Turnover Ratio ONCE's Dividend Growth
ONCE's Roe ONCE's Valuation Ratios ONCE's Financial Strength Ratios ONCE's Gross Profit Growth
ONCE's Roa ONCE's Inventory Turnover Ratio ONCE's Growth Rates ONCE's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2019, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginSep 30 2019 MRQ Gross ProfitSep 30 2019 MRQ Revenue
Neurocrine Biosciences Inc   99.00 %$ 219.865  Millions$ 222.094  Millions
Exelixis Inc   97.23 %$ 264.166  Millions$ 271.703  Millions
Seagen Inc   95.91 %$ 204.540  Millions$ 213.263  Millions
Spark Therapeutics Inc   95.50 %$ 21.437  Millions$ 22.447  Millions
Cyclo Therapeutics Inc   90.92 %$ 0.260  Millions$ 0.286  Millions
Bluebird Bio Inc   90.33 %$ 8.048  Millions$ 8.910  Millions
La Jolla Pharmaceutical Company  90.29 %$ 5.152  Millions$ 5.706  Millions
Biogen Inc   88.06 %$ 3,170.100  Millions$ 3,600.100  Millions
Biocardia Inc   87.63 %$ 0.170  Millions$ 0.194  Millions
Creative Medical Technology Holdings Inc   86.09 %$ 0.050  Millions$ 0.058  Millions
Acorda Therapeutics Inc   83.27 %$ 39.736  Millions$ 47.722  Millions
Regenxbio Inc   83.03 %$ 12.206  Millions$ 14.700  Millions
Amgen Inc   81.94 %$ 4,701.000  Millions$ 5,737.000  Millions
Zeo Scientifix Inc   81.87 %$ 0.479  Millions$ 0.586  Millions
Outlook Therapeutics Inc   81.76 %$ 4.786  Millions$ 5.854  Millions
Gilead Sciences Inc   81.53 %$ 4,569.000  Millions$ 5,604.000  Millions
Titan Pharmaceuticals Inc   80.15 %$ 0.759  Millions$ 0.947  Millions
Lineage Cell Therapeutics Inc   79.89 %$ 0.453  Millions$ 0.567  Millions
Vivosim Labs Inc   78.54 %$ 0.966  Millions$ 1.230  Millions
Adaptive Biotechnologies Corporation  78.51 %$ 20.457  Millions$ 26.058  Millions
Vericel Corporation  69.43 %$ 21.175  Millions$ 30.499  Millions
Orchard Therapeutics Plc  67.99 %$ 1.304  Millions$ 1.918  Millions
Xtant Medical Holdings Inc   66.61 %$ 10.472  Millions$ 15.721  Millions
Bio techne Corp  64.62 %$ 118.414  Millions$ 183.243  Millions
Nanostring Technologies Inc   64.30 %$ 19.679  Millions$ 30.604  Millions
Aerie Pharmaceuticals Inc   57.38 %$ 10.640  Millions$ 18.544  Millions
Repligen Corp  54.75 %$ 38.020  Millions$ 69.445  Millions
Polarityte Inc   53.76 %$ 0.750  Millions$ 1.395  Millions
Premier Biomedical Inc  52.29 %$ 0.002  Millions$ 0.003  Millions
Halozyme Therapeutics Inc   51.69 %$ 23.897  Millions$ 46.230  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.